NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Solid Biosciences Inc. (SLDB) Stock Analysis

Solid Biosciences Inc. (SLDB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SLDB

$6.41

+$0.01 (+0.16%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLDB with… →

SLDB Key Statistics

As of Oct 21, 2026
Trading
Open
$6.46
Previous Close
$6.40
Day's Range
6.32–6.58
52-Week Range
3.79–11.45
Volume
1.15M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.47
Valuation
Market Cap
$687.31M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.89
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$174.33M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
107.23M
1-Year Return
+6.66%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
1.16M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SLDB closed at $6.41, +6.66% over 1 year.

Solid Biosciences Inc. (SLDB) has a market capitalization of $687.31M.

In fiscal 2025, SLDB reported revenue of $0.00.

SLDB Stock Return by Calendar Year

Solid Biosciences Inc. (SLDB) return since Jan 2018: what $10,000 became

1 year
$10,000 $10,666
+6.66%
5 years
$10,000 $1,988
−80.12%
Since Jan 2018
$10,000 $189
−98.11%

If you had invested $10,000 in Solid Biosciences Inc. (SLDB) at the close on January 26, 2018, the earliest close on record here, it would have been worth $189 at the close on October 21, 2026: −98.11% in total, −36.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.65%
2025+41.00%
2024−34.85%
2023+14.13%
2022−79.50%
2021−76.91%
2020+70.34%
2019−83.40%
2018+18.48%

As of October 21, 2026.

SLDB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$174.33M—
2024$0.00−$124.70M—
2023$0.00−$96.02M—
2022$8.09M−$85.98M−1,062.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$179.21M−$174.33M—
2024$0.00—−$129.73M−$124.70M—
2023$0.00—−$104.32M−$96.02M—
2022$8.09M—−$99.27M−$85.98M−1,062.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Solid Biosciences Inc. (SLDB) carries a market capitalisation of $687.31M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 121.

Over the past 52 weeks the price has ranged from $3.79 to $11.45. The most recent close on file for SLDB is $6.41, dated October 21, 2026. That is +$0.01 (+0.16%) against the previous close. The latest close sits 69.13% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $174.33M. Earnings per share on a trailing basis come to −1.89.

Across the 4 fiscal years on file, revenue moves from $8.09M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is +6.66%. Across 5 years the annualized return works out at −27.61%. Beta against the wider market is reported at 2.47. Daily returns over the trailing 8 years annualize to a volatility of 105.68%.

Growth & Income

No dividend is on file for SLDB.

So far in 2026 the total return is +13.65%. Across the complete calendar years on file, 2020 returned +70.34% and 2019 returned −83.40%. Of the 8 complete calendar years on file, 4 finished higher.

Peer Comparison

Solid Biosciences Inc. (SLDB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Solid Biosciences Inc. SLDB $687.31M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Solid Biosciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Solid Biosciences Inc.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Visit website →